| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
102.61(B) |
| Last
Volume: |
833,166 |
Avg
Vol: |
763,886 |
| 52
Week Range: |
$692.45 - $993.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
168,291 |
239,408 |
282,159 |
440,143 |
| Total Sell Value |
$164,172,161 |
$229,422,190 |
$264,894,282 |
$375,408,932 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
12 |
43 |
60 |
121 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sing George L |
Director |
– • – |
2020-05-29 |
4 |
S |
$595.00 |
$596,510 |
I/I |
(1,000) |
7,700 |
|
-10% |
|
| Sanofi-Aventis |
|
• • • |
2020-05-29 |
4 |
S |
$509.85 |
$1,223,411,587 |
I/I |
(2,399,552) |
400,000 |
|
-10% |
|
| Sanofi-Aventis |
|
• • • |
2020-05-29 |
4 |
S |
$509.85 |
$2,147,483,647 |
D/D |
(20,421,899) |
0 |
|
-10% |
|
| Sing George L |
Director |
– • – |
2020-05-28 |
4 |
S |
$578.00 |
$579,000 |
I/I |
(1,000) |
8,200 |
|
-10% |
|
| Goldstein Joseph L |
Director |
– • – |
2020-05-28 |
4 |
S |
$578.94 |
$578,940 |
D/D |
(1,000) |
6,643 |
|
-10% |
|
| Vagelos P Roy |
Director |
– • – |
2020-05-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
73,100 |
234,649 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2020-05-21 |
4 |
AS |
$577.37 |
$452,178 |
D/D |
(783) |
307,749 |
|
1% |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2020-05-21 |
4 |
AS |
$556.79 |
$83,984,786 |
D/D |
(148,811) |
308,532 |
|
1% |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2020-05-20 |
4 |
D |
$570.97 |
$91,150,793 |
D/D |
(159,642) |
457,343 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2020-05-20 |
4 |
OE |
$30.63 |
$9,571,875 |
D/D |
312,500 |
497,063 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-05-15 |
4 |
AS |
$572.00 |
$4,793,360 |
D/D |
(8,380) |
14,438 |
|
-1% |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-05-14 |
4 |
D |
$573.18 |
$5,692,251 |
D/D |
(9,931) |
22,818 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-05-14 |
4 |
OE |
$59.20 |
$1,084,011 |
D/D |
18,311 |
32,749 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2020-05-13 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
10,349 |
|
- |
|
| Sing George L |
Director |
– • – |
2020-05-13 |
4 |
S |
$580.00 |
$2,900,000 |
D/D |
(5,000) |
115,415 |
|
2% |
|
| Sing George L |
Director |
– • – |
2020-05-13 |
4 |
OE |
$33.42 |
$167,100 |
D/D |
5,000 |
120,415 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2020-05-12 |
4 |
AS |
$557.51 |
$85,908,042 |
D/D |
(150,922) |
474,499 |
|
-0% |
|
| Sing George L |
Director |
– • – |
2020-05-11 |
4 |
S |
$575.00 |
$488,750 |
I/I |
(850) |
8,700 |
|
3% |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2020-05-11 |
4 |
D |
$571.43 |
$92,330,517 |
D/D |
(161,578) |
625,421 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2020-05-11 |
4 |
OE |
$30.63 |
$9,571,875 |
D/D |
312,500 |
722,368 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-05-11 |
4 |
S |
$567.50 |
$3,021,289 |
D/D |
(5,305) |
11,380 |
|
3% |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-05-08 |
4 |
D |
$560.67 |
$4,034,021 |
D/D |
(7,195) |
16,685 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-05-08 |
4 |
OE |
$52.03 |
$650,375 |
D/D |
12,500 |
23,880 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-05-07 |
4 |
S |
$556.92 |
$22,337,306 |
D/D |
(39,583) |
28,251 |
|
-4% |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-05-07 |
4 |
S |
$565.64 |
$2,899,461 |
D/D |
(5,118) |
643 |
|
-4% |
|
1367 Records found
|
|
Page 29 of 55 |
|
|
10.25 (1.06%) 
